期刊
VACCINE
卷 39, 期 32, 页码 4516-4523出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.06.034
关键词
Cholera; Oral Cholera Vaccine; Dose interval; Immunogenicity; Zambia
资金
- Bill AMP
- Melinda Gates Foundation [OPP1148763]
- National institute of Allergy and Infectious Disease [5R01AI123422]
Two-dose killed oral cholera vaccines (OCV) are widely used for cholera control. This study compared the vibriocidal response induced by OCV with standard dose-interval (2 weeks) and extended dose-interval (6 months) for the second dose. The findings indicated that vibriocidal titers 14 days after the second dose were similar between the standard and extended dose-interval groups.
Two-dose killed oral cholera vaccines (OCV) are currently being used widely to control cholera. The stan-dard dose-interval for OCV is 2 weeks; however, during emergency use of the vaccine, it may be more appropriate to use the available doses to quickly give a single dose to more people and give a delayed second dose when more vaccine becomes available. This study is an open label, randomized, phase 2 clinical trial of the vibriocidal response induced by OCV, comparing the responses when the second dose was given either 2 weeks (standard dose interval) or 6 months (extended dose interval) after the first dose. Vaccine was administered to healthy participants > 1 year of age living in the Lukanga Swamps area of Zambia. Three age cohorts (<5 years, 5-14 years, and > 15 years) were randomized to the either dose-interval. The primary outcome was the vibriocidal GMT 14 days after the second dose. 156 of 172 subjects enrolled in the study were included in this analysis. The Inaba vibriocidal titers were not significantly different 14 days post dose two for a standard dose-interval GMT: 45.6 (32- 64.9), as compared to the GMT 47.6 (32.6-69.3), for the extended dose-interval, (p = 0.87). However, the Ogawa vibriocidal GMTs were significantly higher 14 days post dose two for the extended-dose inter-val at 87.6 (58.9-130.4) compared to the standard dose-interval group at 49.7 (34.1-72.3), p = 0.04. Vibriocidal seroconversion rates (a > 4-fold rise in vibriocidal titer) were not significantly different between dose-interval groups. This study demonstrated that vibriocidal titers 14 days after a second dose when given at an extended\ dose interval were similar to the standard dose-interval. The findings suggest that a flexible dosing schedule may be considered when epidemiologically appropriate. The trial was registered at Clinical Trials.gov (NCT03373669). (c) 2021 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据